Thumbs Up/Thumbs Down: The new buzz in R&D, blockbuster work on a budget and why what’s dead may never die
Endpoints assesses the big biopharma R&D stories of the week, with a little added commentary on what they mean for the industry.
Bioelectronics gets a star turn
Let’s get it out front. I have a weakness for big thinking about new R&D fields. So when I got wind of the tie-up between GlaxoSmithKline and Verily (Lord Google’s life science arm), I got up at 3 am and wrote the story. The idea that nanotech based devices can be used to orchestrate a series of electric pulses to treat a disease can only thrill a real R&D enthusiast. And at this stage, everything has great potential. We’re a couple of years out from proof of concept, so this is far from a commercial story. (Which, let’s face it, is what GSK really needs now.) Science lovers will follow it as closely as they can. Count me in.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.